fbpx

Omnipod® 5 Automated Insulin Delivery System

Take your insulin delivery to the next level with the Omnipod® 5 Automated Insulin Delivery System.

This product builds on the tubeless insulin delivery offered by its predecessor, the popular Omnipod DASH Insulin Management System – both systems include a Pod worn on your body that can deliver continuous insulin for up to three days. However, the Omnipod 5 is fully automated and compatible with the Dexcom® G6 Continuous Glucose Monitor System, allowing people with diabetes to avoid highs and lows like never before.*

Like the Omnipod DASH system, the Omnipod 5 relies on a tubeless, waterproof† Pod for insulin delivery. But now, your Pod can make changes to your insulin delivery rate as needed, thanks to SmartAdjust™ technology. And for maximum convenience, you’ll be able to control the Omnipod 5 with a compatible smartphone.‡

The best place to get your Omnipod 5 system is ADS. Please call our Customer Care Team at 1-866-422-4866 or fill out the form below to see if you qualify for an insulin management system with $0 out-of-pocket costs.§

6 + 2 = ?

Features

  • SmartAdjust: Your Omnipod 5 will raise, lower, or pause insulin delivery every five minutes based on how close you are to your target level.
  • Activity mode: Since glucose levels usually change during exercise, this mode can temporarily raise or lower insulin delivery to match.
  • SmartBolus: Unlike other AID systems, Omnipod 5 has an integrated bolus calculator that can take CGM data and trends into account.

All the benefits of Omnipod DASH: The Pod is still a waterproof,† tubeless alternative to daily insulin injections.

Uses

With the Omnipod 5 Automated Insulin Delivery System, people with type 1 diabetes can automatically take care of their insulin delivery needs. For added convenience, the system is compatible with the Dexcom G6 Continuous Glucose Monitor System and boasts various new features

Omnipod 5 Frequently Asked Questions

The Omnipod 5 Automated Insulin Delivery System has entered full market release and can be ordered from ADS.

The FDA approved the Omnipod 5 system in early 2022. The system is authorized for use by individuals aged two and older who have type 1 diabetes.

The Pod used in the Omnipod 5 system can hold up to 200 U of rapid-acting insulin.

No – the Omnipod 5 Automated Insulin Delivery System is designed specifically for use with the Dexcom G6 Continuous Glucose Monitor System.

The FDA has approved the Omnipod 5 system authorized for use by individuals aged two and older who have type 1 diabetes.

As of April 2022, the Omnipod 5 system has only received FDA approval for use by people with type 1 diabetes. However, Insulet has released results from a feasibility study regarding the potential use of this system by people who have type 2 diabetes.

*Brown S. et al. Diabetes Care. 2021;44:1630-1640. Prospective pivotal trial in 240 participants with T1D aged 6 – 70 yrs. Study included a 14-day standard therapy (ST) phase followed by a 3-month Omnipod 5 hybrid closed-loop (HCL) phase. Mean time in range (70-180mg/dL) in adults/adolescents and children as measured by CGM: ST = 64.7%, 3-mo Omnipod 5 = 73.9%, P<0.0001; ST = 52.5%, 3-mo Omnipod 5 = 68.0%, P<0.0001, respectively. Mean time > 180 mg/dL (12AM-6AM) as in adults/adolescents and children, ST vs. 3-mo Omnipod 5: 32.1% vs. 20.7%; 42.2% vs. 20.7%, P<0.0001, respectively. Mean time >180 mg/dL (6AM -12AM) in adults/adolescents and children, ST vs. 3-mo Omnipod 5: 32.6% vs. 26.1%; 46.4% vs. 33.4%, P<0.0001, respectively. Median time in <70 mg/dL (12AM-6AM) in adults/adolescents and children, ST vs. 3-mo Omnipod 5: 2.07% vs. 0.82%,P<0.0001; 0.78% vs. 0.78%, P=0.0456, respectively. Median time <70 mg/dL (6AM-12AM) in adults/adolescents and children, ST vs. 3-mo Omnipod 5: 1.91% vs. 1.08%, P<0.0001; 1.17% vs. 1.62%, P=0.2545, respectively. Results measured by CGM. †The Pod has an IP28 rating for up to 25 feet for 60 minutes. The controller is not waterproof. ‡For a list of compatible smartphone devices visit omnipod.com/compatibility. §For qualified persons with applicable in-network insurance and subject to CGM coverage requirements. Deductibles, co-pays, and other conditions apply. Speak to an ADS representative and your insurance company to confirm your coverage and costs. [/av_textblock] [av_heading heading='Risk Statement' tag='h3' link='' link_target='' style='' size='' subheading_active='' subheading_size='' margin='' padding='10' color='' custom_font='' custom_class='' id='' admin_preview_bg='' av-desktop-hide='' av-medium-hide='' av-small-hide='' av-mini-hide='' av-medium-font-size-title='' av-small-font-size-title='' av-mini-font-size-title='' av-medium-font-size='' av-small-font-size='' av-mini-font-size='' av_uid='av-2unjxm'][/av_heading] [av_textblock textblock_styling_align='' textblock_styling='' textblock_styling_gap='' textblock_styling_mobile='' size='12' av-medium-font-size='' av-small-font-size='' av-mini-font-size='' font_color='' color='' id='' custom_class='' template_class='' av_uid='av-kzozlgq4-1' sc_version='1.0' admin_preview_bg=''] The Omnipod 5 Automated Insulin Delivery System is indicated for use by individuals with type 1 diabetes mellitus in persons 6 years of age and older. The Omnipod 5 System is intended for single patient, home use and requires a prescription. The Omnipod 5 System is compatible with the following U-100 insulins: NovoLog®, Humalog®, and Admelog®. The Omnipod 5 ACE Pump (Pod) is intended for the subcutaneous delivery of insulin, at set and variable rates, for the management of diabetes mellitus in persons requiring insulin. The Omnipod 5 ACE Pump is able to reliably and securely communicate with compatible, digitally connected devices, including automated insulin dosing software, to receive, execute, and confirm commands from these devices. SmartAdjust™ technology is intended for use with compatible integrated continuous glucose monitors (iCGM) and alternate controller enabled (ACE) pumps to automatically increase, decrease, and pause delivery of insulin based on current and predicted glucose values. The  Omnipod 5 SmartBolus Calculator is intended to calculate a suggested bolus dose based on user-entered carbohydrates, most recent sensor glucose value (or blood glucose reading if using fingerstick), rate of change of the sensor glucose (if applicable), insulin on board (IOB), and programmable correction factor, insulin to carbohydrate ratio, and target glucose value. WARNING: SmartAdjust technology should NOT be used by anyone under the age of 6 years old. SmartAdjust technology should also NOT be used in people who require less than 6 units of insulin per day as the safety of the technology has not been evaluated in this population.

The Omnipod 5 System is NOT recommended for people who are unable to monitor glucose as recommended by their healthcare provider, are unable to maintain contact with their healthcare provider, are unable to use the Omnipod 5 System according to instructions, are taking hydroxyurea as it could lead to falsely elevated CGM values and result in over-delivery of insulin that can lead to severe hypoglycemia, and do NOT have adequate hearing and/or vision to allow recognition of all functions of the Omnipod 5 System, including alerts, alarms, and reminders. Device components including the Pod, CGM transmitter, and CGM sensor must be removed before Magnetic Resonance Imaging (MRI), Computed Tomography (CT) scan, or diathermy treatment. In addition, the Controller and smartphone should be placed outside of the procedure room. Exposure to MRI, CT, or diathermy treatment can damage the components. Visit www.omnipod.com/safety for additional important safety information.

WARNING: DO NOT start to use the Omnipod 5 System or change settings without adequate training and guidance from a healthcare provider. Initiating and adjusting settings incorrectly can result in over-delivery or under-delivery of insulin, which could lead to hypoglycemia or hyperglycemia.